APA (7th ed.) Citation

Liu, X., Li, Y., Li, J., Zhou, J., Guo, J., Pu, Y., . . . Li, X. (2023). Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial. Elsevier.

Chicago Style (17th ed.) Citation

Liu, Xiaoqiang, et al. Comparing Recombinant Human Rabies Monoclonal Antibody (ormutivimab) with Human Rabies Immunoglobulin (HRIG) for Postexposure Prophylaxis: A Phase III, Randomized, Double-blind, Non-inferiority Trial. Elsevier, 2023.

MLA (9th ed.) Citation

Liu, Xiaoqiang, et al. Comparing Recombinant Human Rabies Monoclonal Antibody (ormutivimab) with Human Rabies Immunoglobulin (HRIG) for Postexposure Prophylaxis: A Phase III, Randomized, Double-blind, Non-inferiority Trial. Elsevier, 2023.